Immunotherapy combo tested in Tough-to-Treat breast cancer
NCT ID NCT03095352
Summary
This study tested if adding an immunotherapy drug (pembrolizumab) to a standard chemotherapy (carboplatin) could better control breast cancer that had returned to the chest wall. It involved 76 patients whose cancer had stopped responding to prior hormone therapies or was a type called triple-negative. The main goal was to see if the combination kept the cancer from growing for at least 18 weeks more often than chemotherapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
-
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15232, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.